| Literature DB >> 25888136 |
Seid Muhie1,2, Aarti Gautam3, James Meyerhoff4, Nabarun Chakraborty5, Rasha Hammamieh6, Marti Jett7.
Abstract
BACKGROUND: Social-stress mouse model, based on the resident-intruder paradigm was used to simulate features of human post-traumatic stress disorder (PTSD). The model involved exposure of an intruder (subject) mouse to a resident aggressor mouse followed by exposure to trauma reminders with rest periods. C57BL/6 mice exposed to SJL aggressor mice exhibited behaviors suggested as PTSD-in-mouse phenotypes: intermittent freezing, reduced locomotion, avoidance of the aggressor-associated cue and apparent startled jumping. Brain tissues (amygdala, hippocampus, medial prefrontal cortex, septal region, corpus striatum and ventral striatum) from subject (aggressor exposed: Agg-E) and control C57BL/6 mice were collected at one, 10 and 42 days post aggressor exposure sessions. Transcripts in these brain regions were assayed using Agilent's mouse genome-wide arrays.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25888136 PMCID: PMC4359441 DOI: 10.1186/s13041-015-0104-3
Source DB: PubMed Journal: Mol Brain ISSN: 1756-6606 Impact factor: 4.041
Summary of experimental conditions and collected tissues
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| T5R1 | Agg-E_T5R1 | C57BL/6 | SJL | 5 | 1 |
| C-ctr_5R1 | C57BL/6 | SJL | 5 | 1 | |
| T5R10 | Agg_E_T5R10 | C57BL/6 | SJL | 5 | 10 |
| C-ctr_T5R10 | C57BL/6 | SJL | 5 | 10 | |
| T10R1 | Agg-E_T10R1 | C57BL/6 | SJL | 10 | 1 |
| C-ctr_T10R1 | C57BL/6 | SJL | 10 | 1 | |
| T10R42 | Agg-E_T10R42 | C57BL/6 | SJL | 10 | 42 |
| C-ctr_T10R42 | C57BL/6 | SJL | 10 | 42 |
*collected brain regions: HC: hippocampus, AY: amygdala, MPFC: medial prefrontal cortex, VS: ventral striatum or nucleus accumbens, SE: septal region, ST: corpus striatum.
Figure 1Differentially expressed genes (DEGs) across brain regions at different time points (T5R1, T5R10, T10R1 and T10R42). The scatter plots show both log2 -fold changes and negative log10 p-values in six brain regions (across) and four time-points (down); the numbers of up- and down-regulated transcripts in each group are also shown. Key: amygdala (AY), hippocampus (HC), medial prefrontal cortex (MPFC), septal region (SE), corpus striatum (ST), and ventral striatum (VS), T: number of days of trauma or aggressor exposure; R: post-trauma tissue collection days; Agg-E: aggressor-exposed.
Figure 2Modular networks of DEGs associated with circadian clock, behavioral response and synaptic transmission; each module (nodes of the same color) forms a functional module.
Figure 3Networks of DEGs involved in associative learning, fear memory extinction, and aggressive and territorial behaviors. Nodes are colored using AY_T10R1 and HC_T10R1.
Figure 4Networks of DEGs involved in circadian rhythm and corticotropin releasing factor signaling. Nodes are colored using AY_T10R1 and HC_T10R1.
Figure 5Activation pattern of anxiety-like behavior in amygdala (AY), hippocampus (HC) and medial prefrontal cortex (MPFC) and expression directions of associated genes.
Figure 6Behavioral response and neurological disorders associated with DEGs of brain regions at four different time points.
Figure 7Neuronal signaling, synaptic plasticity and neurogenesis associated with DEGs of brain regions at four different time points.
Differentially regulated genes (DEGs) significantly associated with different behavioral responses, neuronal signaling processes and comorbid conditions
|
|
| |
|---|---|---|
| Behavioral response | ||
| anxiety | 4.37E-17 | APP,BDNF,CCK,CNR1,CREB1,CRH,CRHR1,DRD2, FKBP5,FOS,MAPK1,NPY,NTRK2 |
| anxiety-like behavior | 3.10E-10 | APP,BDNF,CCK,CRH,CRHR1,MAPK1 |
| cognition | 9.54E-24 | AKT1,APP,BDNF,CNR1,CREB1,CRH,CRHR1, DRD2,EP300,ERK1/2,FOS,GNAI1,HDAC3,KL,MAPK1,MAPK3,NGF,NPY,NR3C1,NTRK1,NTRK2,PI3K (complex),THRB |
| cognitive impairment | 2.94E-10 | APP,BDNF,CNR1,CRH,DRD2,LEP,NGF,NPY |
| conditioning | 4.06E-12 | APP,BDNF,CNR1,CREB1,CRHR1,DRD2,ERK1/2, GNAI1,HDAC2,MAPK1,NPY |
| depressive disorder | 7.59E-10 | APP,BDNF,CCKBR,CREB1,CRH,DRD2,FKBP5, NR3C1,NTRK1,THRB |
| emotional behavior | 3.83E-15 | APP,BDNF,CCK,CNR1,CREB1,CRH,CRHR1,DRD2, MAPK1,MAPK3,NGF,NPY,NTRK2 |
| learning | 1.25E-21 | AKT1,APP,BDNF,CNR1,CREB1,CRH,CRHR1,DRD2, EP300,ERK1/2,FOS,GNAI1,HDAC3,HOMER1,MAPK1,MAPK3,NGF,NPY,NR3C1,NTRK1,NTRK2, PI3K (complex),THRB |
| locomotion | 6.56E-11 | APP,BDNF,CCKBR,CNR1,CRH,CRHR1,DRD2,LEP, NGF,NR3C1,STAT3 |
| long-term memory | 1.37E-15 | APP,BDNF,CREB1,CRH,DRD2,ERK1/2,GNAI1, HDAC3,MAPK1,NTRK2 |
| memory | 5.63E-20 | AKT1,APP,BDNF,CNR1,CREB1,CRH,CRHR1,DRD2, EP300,ERK1/2,GNAI1,HDAC3, HOMER1,MAPK1,NGF,NPY,NR3C1,NTRK1,NTRK2, PI3K (complex) |
| Mood Disorders | 2.80E-10 | AKT1,APP,BDNF,CCKBR,CREB1,CRH,DRD2, FKBP5,NR3C1,NTRK1,PLCG1,THRB |
| neurological signs | 2.63E-11 | AKT1,APP,BDNF,CCKBR,CNR1,CREB1, CTNNB1, DRD2,FOS,LEP,NGF,NPY,NTRK2,PRL |
| neuromuscular disease | 1.45E-10 | AKT1,APP,BDNF,CCKBR,CNR1,CREB1, CTNNB1,DRD2,FOS,LEP,NGF,NPY,NR3C1,NTRK2, PRL |
| object recognition memory | 1.69E-09 | APP,CNR1,EP300,HDAC3,NGF |
| post-traumatic stress disorder | 5.32E-14 | ADRA1A,ADRA1B,ADRA2A,ADRA2B,ADRA2C, ADRB1,CNR1,CNR2,DRD1,DRD2,DRD3,DRD4,DRD5,HTR1A,NR3C1,SLC6A4 |
| recognition memory | 2.36E-13 | APP,CNR1,EP300,GNAI1,HDAC3,MAPK1,NGF, NR3C1 |
| spatial learning | 3.72E-10 | APP,BDNF,CREB1,CRHR1,DRD2,FOS,NGF,NTRK2 |
| spatial memory | 2.95E-11 | AKT1,APP,BDNF,CNR1,CREB1,DRD2,NGF,NPY, NR3C1,PI3K (complex) |
| Neuronal signaling and neurogenesis | ||
| activation of neurons | 1.22E-10 | APP,BDNF,CCK,CNR1,CRH,FOS,LEP,NGF,PI3K (complex) |
| atrophy of neurons | 4.63E-10 | APP,BDNF,NGF,NTRK1,NTRK2 |
| axonogenesis | 1.84E-11 | AKT1,APP,BDNF,CCK,CREB1,DRD2,FOS,NGF,NTRK1,NTRK2 |
| cell death of hippocampal neurons | 1.51E-09 | AKT1,APP,BDNF,CRHR1,DRD2,LEP,NGF, NTRK2 |
| concentration of corticosterone | 1.28E-13 | APP,CNR1,CRH,CRHR1,DRD2,LEP,NPY,NR3C1, NTRK2,STAT3 |
| concentration of cyclic AMP | 3.58E-09 | ADCY,APP,BDNF,CCK,CNR1,CRH,DRD2,LEP,NGF, PRL |
| degeneration of neurons | 2.07E-09 | AKT1,APP,BDNF,CNR1,CREB1,EP300,NGF,NTRK2, STAT3 |
| dendritic growth/branching | 6.77E-11 | AKT1,APP,BDNF,CNR1,CRH,CRHR1,DRD2,NGF, NTRK2 |
| depolarization of cells | 1.34E-10 | APP,BDNF,CCK,CRH,FOS,LEP,NPY |
| disorder of basal ganglia | 2.28E-10 | AKT1,APP,BDNF,CCKBR,CNR1,CREB1, CTNNB1,DRD2,FOS,LEP,NGF,NPY,NTRK2,PRL |
| excitation of neurons | 4.23E-12 | APP,BDNF,CCK,CRH,FOS,NGF,NPY,NTRK2 |
| length of dendrites | 1.78E-12 | APP,BDNF,CRH,CRHR1,NGF,NTRK2 |
| long-term potentiation | 4.96E-15 | APP,BDNF,CNR1,CREB1,CRHR1,DRD2,ERK1/2, GNAI1,HDAC2,MAPK1,MAPK3,NGF,NPY,NTRK2, PI3K (complex) |
| long-term potentiation of synapse | 1.44E-12 | APP,BDNF,CNR1,CREB1,DRD2,GNAI1,HDAC2, MAPK3,NTRK2 |
| loss of dorsal root ganglion cells | 4.01E-10 | BDNF,NGF,NTRK1,NTRK2 |
| mobilization of Ca2+ | 3.95E-10 | BDNF,CCK,DRD2,GNAI1,GNB2, inositol triphosphate,NGF,NPY,PI3K (complex), PLCG1,RXFP3,SRC |
| neuronal cell death | 1.68E-15 | AKT1,APP,BDNF,CNR1,CREB1,CRHR1,CTNNB1,DRD2,EP300,ERK1/2,FOS,HDAC3,LEP,MAPK1,NGF,NR3C1,NTRK1,NTRK2,PI3K (complex),SRC,STAT3 |
| neuroprotection | 4.24E-09 | AKT1,APP,BDNF,CNR1,CRH,CRHR1,LEP,NGF,PI3K (complex) |
| neurotransmission | 3.60E-17 | APP,BDNF,CCK,CCKBR,CNR1,CRH,CRHR1, CTNNB1,DRD2,ERK1/2,GNAI1,HDAC2,LEP,NGF, NPY,NR3C1,SRC |
| proliferation of neuronal cells | 2.13E-09 | BDNF,CNR1,CTNNB1,DRD2,ERK1/2,LEP,NGF, NTRK2,PI3K (complex),STAT3 |
| quantity of ACTH in blood | 4.32E-09 | CNR1,DRD2,NR3C1,NTRK2 |
| quantity of neurons | 4.71E-12 | APP,BDNF,CREB1,DRD2,ERK1/2,LEP,NGF,NPY, NTRK1,NTRK2,PRL,THRB |
| quantity of pituitary cells | 2.10E-11 | CRH,CTNNB1,DRD2,LEP,PRL,THRB |
| release of acetylcholine | 3.84E-09 | APP,BDNF,CNR1,CRH,DRD2,NGF |
| release of Ca2+ | 3.82E-09 | AKT1,APP,BDNF,CCK,DRD2, inositol triphosphate,LEP,NGF,PI3K (complex),PLCG1,SRC |
| release of catecholamine | 3.32E-14 | APP,BDNF,CNR1,CRHR1,DRD2,LEP,NGF,NPY, NTRK1,NTRK2,PRL,SRC |
| release of dopamine | 1.84E-11 | APP,BDNF,CNR1,CRHR1,DRD2,LEP,NGF,NTRK2, PRL |
| release of L-glutamic acid | 1.12E-11 | ADCY,APP,BDNF,CCK,CNR1,CRH,DRD2,LEP,NGF, NPY |
| secretion of catecholamine | 2.06E-12 | AKT1,APP,CNR1,CRH,CRHR1,DRD2,NPY,NTRK1 |
| secretion of corticosterone | 4.27E-12 | BDNF,CRH,CRHR1,DRD2,LEP,NPY |
| secretion of neurotransmitter | 3.44E-10 | CCK,CNR1,CRH,DRD2,NGF,NPY,NTRK1,NTRK2 |
| stimulation of neurons | 4.28E-13 | APP,BDNF,CCK,CRH,FOS,LEP,NGF,NPY,NTRK2 |
| synaptogenesis | 2.22E-10 | APP,BDNF,CREB1,CTNNB1,HDAC2,NGF,NTRK1, NTRK2 |
| synthesis of neurotransmitter | 7.69E-10 | AKT1,APP,BDNF,CRH,NGF,NTRK1 |
| synthesis of steroid | 3.71E-09 | APP,BDNF,CREB1,CRH,CRHR1,LEP,MAPK1,NR3C1,PI3K (complex),PRL,PROX1 |
| Comorbid conditions | ||
| chronic inflammation | 1.56E-11 | ACE,ADORA2B,ADORA3,AGER,AOC3,C3,CCL5,CCR5,CD24A,CD28,CD47,CNR1,COX2,EDNRA,FABP4,FCER1A,FCER1G,FCGR1,FCGR3,GIF,HSPD1,IDO1,IL1B,ITGA2,JAK2,LBP,LTA,MIF,PDE5A,PIK3CG,PLA2G4A,PRKCA,PTGER3,PTGS2,STAT5A,STAT5B,TAC1,TGM2,TLR4,TNFRSF11A,TNFRSF1A,TNFSF11,H2-DMA,H2-DMB1,H2BFM,HADH,HNF1A,HPSE,HSPD1,HTT,ICA1,IFNGR2,IKBKG,IL12B,IL1R1,IL2,ILDR2,INPP5K,INPPL1,INSR,IRAK1,IRF1,IRS3,JAK2,KCNJ11,KHK,KRAS,LARS,LEP,LEPR,LEPROT,LIPE,LMAN1L,LPIN1,LTA, MAP3K7,MAPK8,MYD88,MYO5A,NCK1,NFKB1,NFKB2,NFKBIB,NFKB1,NFKB2,NFKBIB,RELA |
| myocardial infarction | 6.49E-12 | AKT1,AKT1,APP,CNR1,CREB1,CTNNB1,DRD2,EP300, ERK1/2,FOS,HDAC2,HDAC3,KL,LEP,MAPK1, MAPK3,NPY,NR3C1,STAT3,THRB,GPX3, SRC |
| hypertrophy of cardiomyocytes | 6.16E-06 | AKT1,EP300,HDAC2,LEP,MAPK1,PI3K (complex), STAT3 |
| coronary artery disease | 3.08E-04 | APOE, CNR1,FOS,HDAC2,KL,NR3C1, LEP |
| metabolic disorders: types I and II diabetes | 3.78E-15 | AANAT,ABCC8,ACLY,ACSBG1,ACSBG2,ACSL4,ACSL6,ACVR1C,ADCY8,ADIPOR1,ADIPOR2,AGRP,AKT1,ANXA1,APAF1,APOE,ASIC2,ATM,BAD,BCAR1,CACNA1C,CAMP,CAPN8,CASP3,CBL,CCKAR,CD247,CDK2,CEBPB,CERK,CHUK,CITED1,CNR1,CNR2,CPE,CPLX3,GAD2,GCK,GH,GHRHR,GHRL,GHSR,GLP1R,GPR119,GRB2,GSK3B,GYS1,GZMB,H2DMA,H2DMB1,H2Q1,H2BFM,HADH,HNF1A,HPSE,HSPD1,HTT,ICA1,IFNGR2,IKBKG,ILDR2,INPP5K,INPPL1,INSR,IRAK1,IRS3,JAK2,KCNJ11,KHK,KRAS,LARS,LEP,LEPR,LEPROT,LIPE,LMAN1L,LPIN1,LTA,MAP2K2,MAP3K7,MAPK8,MC4R,MRAS,MTOR,MYO5A,NCK1,NGFR,NOS2,NPY,NRAS,NSMAF,OCRL,PAK1,SGK1,SH2B2,SIK2,SLC2A4,SLC2A8,SLC30A8,SMAD2,SOCS1,SORBS1,SORT1,SOS1,SOS2,SRC,STAT1,STAT3,STX1A,STXBP4,SYNJ2,SYP,TLN1,TLN2,TRADD,TRAF6,TRIB3,TRIP10,TSC1,TSC2,VAMP2,VDR,WDTC1,ZFP106 |
| weight gain and obesity | 4.33E-10 | APP,BDNF,CNR1,CRH,DRD2,FOS,LEP,NPY,NTRK2, STAT3,CRK,CYB5R4,CYP27B1,DGAT1,DOK4,EGR1,EIF2AK3,EIF4EBP2,ENPP7,FADD,FAM3B,FAS,FASL,FCER1G,FFAR1,FKBP1B,FOXC2,FOXO4,FRS3,FYN,GAB1,PCLO,PCSK9,PDE3B,PDIA3,PDK1,PDPK1,PDX1,PHIP,PIAS1,PIK3C2G,PIK3CG,PIK3R5,PKLR,PKM,PLCB2,PLCZ1,PPARG,PPP1R3D,PRF1,PRKAR2B,PRKCD,PTEN,PTPN2,PTPRA,RAF1,RAPGEF4,RBP4,RELA,RETN,RHOQ,RIMS2,RIPK1,RPE65,RPS6KB2,RPTOR,RRAS2,SCAP,SCNN1G, |
Figure 8Transcripts – brain-regions interactome for transcripts that passed p-value less than 0.01 and fold change greater than 2.0 in Agg-E groups compared to control groups (across time points).
Figure 9Pathways and biological processes significantly associated with transcripts (with p-value < 0.01, and fold change > 2.0) shown in Figure . Sizes of the hollow-pie sectors were proportional to the number of transcripts associated with that particular pathway or process. Gene expression related processes such as activities of zinc finger protein transcription factors, and splice variant processing were associated with larger numbers of transcripts (and many of these were also shared with pathways related to trauma/fear related behavioral responses).